Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy

Supportive Care in Cancer

Volumn 20, Issue 8, 2012, Pages 1875-1884

  Wu, Shikai ^a   Zhang, Yang ^b   Xu, Liyan ^c   Dai, Yun ^d   Teng, Yuee ^e   Ma, Shanshan ^f   Ho, Seong Hyun ^g,h   Kim, Jong Mook ^g,h   Yu, Seung Shin ^g   Kim, Sunyoung ^g   Song, Santai ^a  

^a Beijing 307 Hospital   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^e CHINA MEDICAL UNIVERSITY   (China)

^f Beijing Northland Biotech Co Ltd   (China)

^g ViroMed Co Ltd   (South Korea)

^h Seoul National University   (South Korea)

Author keywords

Chemotherapy; Interleukin 11; Platelet; Thrombocytopenia

Indexed keywords

ANTINEOPLASTIC AGENT; ARABINOSIDE; CARBOPLATIN; CISPLATIN; CYTARABINE; CYTOSINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSAMIDE; INTERLEUKIN 11; MODIFIED RECOMBINANT HUMAN INTERLEUKIN 11; RECOMBINANT HUMAN INTERLEUKIN 11; UNCLASSIFIED DRUG; VINCRISTINE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMBLYOPIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BONE MARROW SUPPRESSION; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; COLD SWEAT; CONJUNCTIVA DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRY NOSE; DYSPNEA; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HEMATURIA; HOT FLUSH; HUMAN; LEUKOCYTE COUNT; LEUKOCYTURIA; LOW BACK PAIN; LOW DRUG DOSE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OLIGURIA; PARTIAL THROMBOPLASTIN TIME; PATIENT ASSESSMENT; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SHOULDER PAIN; SIDE EFFECT; SINGLE BLIND PROCEDURE; SPUTUM DISCOLORATION; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THRUSH; UREA BLOOD LEVEL; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; CHI-SQUARE DISTRIBUTION; CHINA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-11; MALE; MIDDLE AGED; NEOPLASMS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84863980367     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1290-x     Document Type: Article

References (26)

1. Kuhn JG (2002) Chemotherapy-associated hematopoietic toxicity. Am J Health Syst Pharm 59:S4-S7
2. Vadhan-Raj S, Patel S, Bueso-Ramos C et al (2003) Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol 21:3158-3167
3. Webb IJ, Anderson KC (1999) Risks, costs, and alternatives to platelet transfusions. Leuk Lymphoma 34:71-84
4. Reynolds CH (2000) Clinical efficacy of rhIL-11. Oncology (Williston Park) 14:32-40
5. Du X, Williams DA (1997) Interleukin-11: review of molecular, cell biology, and clinical use. Blood 89:3897-3908
6. Dorner AJ, Goldman SJ, Keith JC Jr (1997) Interleukin-11. BioDrugs 8:418-429
7. Paul SR, Schendel P (1992) The cloning and biologicalcharacterization of recombinant human interleukin-11. Int J Cell Cloning 10(3):135-143
8. Schwertschlag US, Trepicchio WL, Dykstra KH, Keith JC, Turner KJ, Dorner AJ (1999) Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia 13:1307-1315
9. Weich NS, Wang A, Fitzgerald M et al (1997) Recombinant human interleukin-11 directly promotes megakaryocytopoiesis in vitro. Blood 90:3893-3902
10. Neben TY, Loebelenz J, Hayes L et al (1993) Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice. Blood 81:901-908
11. Schlerman FJ, Bree AG, Kaviani MD et al (1996) Thrombopoietic activity of recombinant human interleukin 11 (rHuIL-11) in normal and myelosuppressed nonhuman primates. Stem Cells 14:517-532
12. Leonard JP, Quinto CM, Kozitza MK, Neben TY, Goldman SJ (1994) Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin. Blood 83:1499-1506
13. Smith JW 2nd (2000) Tolerability and side-effect profile of rhIL-11. Oncology (Williston Park) 14:41-47
14. Jung Y, Ahn H, Dong-Sik Kim Yu, Hwang R, Ho S-H, Kim J-M, Kim S, Ma S, Kim S (2011) Improvement of biological and pharmacokinetic features of human interleukin-11 by site-directed mutagenesis. Biochem Biophys Res Commun 405:399-404
15. Cairo MS, Davenport V, Bessmertny O et al (2005) Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. Br J Haematol 128:49-58
16. Dai XF, Yu J, Liu L, Wu G (2008) Value of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor. Zhonghua Zhong Liu Za Zhi 30:623-625
17. World Health Organization (1979) WHO handbook for reporting results of cancer treatment. http://whqlibdoc.who.int/publications/9241700483.pdf. Geneva, Switzerland. WHO Offset Publication No 48;2:P16
18. Elting LS, Rubenstein EB, Martin CG et al (2001) Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 19:1137-1146
19. Li J, Yang C, Xia Y et al (2001) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98:3241-3248
20. Cantor SB, Elting LS, Hudson DV Jr, Rubenstein EB (2003) Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. Cancer 97:3099-3106
21. Gordon MS, McCaskill-Stevens WJ, Battiato LA et al (1996) A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 87:3615-3624
22. Kuter DJ, Begley CG (2002) Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 100:3457-3469
23. Jamali F, Lemery S, Ayalew K et al (2009) Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Oncology (Williston Park) 23:704-709
24. Dmytrijuk A, Robie-Suh K, Rieves D, Pazdur R (2009) Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Oncology (Williston Park) 23:1171-1177
25. Levy B, Arnason JE, Bussel JB (2008) The use of secondgeneration thrombopoietic agents for chemotherapy-induced thrombocytopenia. Curr Opin Oncol 20:690-696
26. Engel C, Loeffler M, Franke H, Schmitz S (1999) Endogenous thrombopoietin serum levels during multicycle chemotherapy. Br J Haematol 105:832-838